Trial Profile

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gallium 68 PNT 6555 (Primary) ; Lutetium 177 PNT 6555 (Primary)
Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Malignant melanoma; Mouth neoplasm; Nasopharyngeal cancer; Oesophageal cancer; Oropharyngeal cancer; Pancreatic cancer; Pharyngeal neoplasms; Skin cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms FRONTIER
Sponsors Eli Lilly and Company; POINT Biopharma

25 Jun 2025 Status changed from active, no longer recruiting to discontinued. ( Business decision)
01 Nov 2024 Planned number of patients changed from 30 to 24.
01 Nov 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com